9580 Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices 

trachoma, making it the most prevalent 

form of infectious preventable 

blindness. Urogenital infections are the 

leading cause of bacterial sexually 

transmitted disease in both 

industrialized and developing nations. 

Moreover, sexually transmitted diseases 

are risk factors for infertility, the 

transmission of HIV, and human 

papilloma virus-induced cervical 

neoplasia. Control of C. trachomatis 

infections is an important public health 

goal. Unexpectedly, however, aggressive 

infection control measures based on 

early detection and antibiotic treatment 

have resulted in an increase in infection 

rates, most likely by interfering with 

natural immunity, a concept suggested 

by studies performed in experimental 

infection models. Effective management 

of chlamydial disease will likely require 

the development of an efficacious 

vaccine. 

This technology claims vaccine 

compositions that comprise an 

immunologically effective amount of 

PmpD protein from C. trachomatis. Also 

claimed in the application are methods 

of immunizing individuals against C. 

trachomatis. PmpD is an antigenically 

stable pan-neutralizing target that, in 

theory, would provide protection 

against all human strains, thus allowing 

the development of a univalent vaccine 

that is efficacious against both blinding 

trachoma and sexually transmitted 

disease. 

Application: Prophylactics against C. 

trachomatis. 

Developmental Status: Preclinical 

studies have been performed. 

Inventors: Harlan Caldwell and 

Deborah Crane (NIAID). 

Publication: DD Crane et al. 

Chlamydia trachomatis polymorphic 

membrane protein D is a speciescommon pan-neutralizing antigen. Proc 

Natl Acad Sci USA. 2006 Feb 

7;103(6):1894–1899. 

Patent Status: PCT Patent Application 

No. PCT/US2007/001213 filed 16 Jan 

2007, which published as WO 2007/ 

082105 on 19 Jul 2007 (HHS Reference 

No. E–031–2006/0–PCT–02). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Peter A. Soukas, 

J.D.; 301/435–4646; 

soukasp@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIAID Laboratory of Intracellular 

Parasites is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize PmpD vaccine 

development. Please contact Harlan D. 

Caldwell, at hcaldwell@niaid.nih.gov or 

406–363–9333 for more information. 

Dated: February 11, 2008. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–3164 Filed 2–20–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel. 

Date: March 19, 2008. 

Time: 2 pm to 5 pm. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Rebecca Wagenaar Miller, 

PhD., Scientific Review Officer, Scientific 

Review Branch, National Inst of Dental & 

Craniofacial Research, National Institutes of 

Health, 6701 Democracy, Rm 666, Bethesda, 

MD 20892, 301–594–0652, 

rwagenaa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: February 13, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–771 Filed 2–20–08; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel; Review RFA DE08–008, 

Centers for Research to Reduce Disparities in 

Oral Health. 

Date: March 5–6, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Plaza, 10 Thomas 

Circle, NW., Washington, DC 20005. 

Contact Person: Mario Rinaudo, MD, 

Scientific Review Officer, Scientific Review 

Branch, National Inst of Dental & Craniofacial 

Research, National Institutes of Health, 6701 

Democracy Blvd (DEM 1), RM 670 MSC4878, 

Bethesda, MD 20892, 301–594–2904) 

mrinaudo@nidcr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

February 13, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–772 Filed 2–20–08: 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases, Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 


pwalker on PROD1PC71 with NOTICES